Compare · INDV vs NVS
INDV vs NVS
Side-by-side comparison of Indivior Pharmaceuticals Inc. (INDV) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INDV and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $293.40B, about 58.0x INDV ($5.06B).
- Over the past year, INDV is up 153.1% and NVS is up 34.6% - INDV leads by 118.5 points.
- INDV has been more active in the news (2 items in the past 4 weeks vs 1 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 7 for INDV).
- Company
- Indivior Pharmaceuticals Inc.
- Novartis AG
- Price
- $40.54-0.07%
- $153.72+0.64%
- Market cap
- $5.06B
- $293.40B
- 1M return
- +6.59%
- +1.89%
- 1Y return
- +153.14%
- +34.60%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 1
- Recent ratings
- 7
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest INDV
- Chief Scientific Officer Heidbreder Christian sold $764,628 worth of shares (18,586 units at $41.14) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 209,337 units (SEC Form 4)
- Chief Executive Officer Ciaffoni Joseph converted options into 1,266,903 shares and covered exercise/tax liability with 612,549 shares, increasing direct ownership by 481% to 790,330 units (SEC Form 4) to cover taxes
- Barclays initiated coverage on Indivior with a new price target
- Chief Scientific Officer Heidbreder Christian sold $707,383 worth of shares (18,586 units at $38.06) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 227,923 units (SEC Form 4)
- Chief Financial Officer Preblick Ryan sold $1,357,200 worth of shares (36,000 units at $37.70) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 284,751 units (SEC Form 4)
- New Studies Show Adherence to Monthly Injectable Buprenorphine is Associated with Relapse Reduction and Lower Healthcare Utilization
- Indivior Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders
- Director Thompson Juliet covered exercise/tax liability with 1,117 shares and was granted 6,518 shares, increasing direct ownership by 71% to 12,973 units (SEC Form 4) (withholding tax)
- Director Humphreys Keith was granted 6,518 shares, increasing direct ownership by 68% to 16,042 units (SEC Form 4)
- Director Kingsley Stuart A was granted 6,518 shares, increasing direct ownership by 117% to 12,100 units (SEC Form 4)
Latest NVS
- The Quest to Repair What Multiple Sclerosis Takes Away
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- Novartis AG upgraded by Argus with a new price target
- Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
- SEC Form S-8 filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form 6-K filed by Novartis AG
- SEC Form IRANNOTICE filed by Novartis AG